EUVIMEDEUVIMED entdecken
Open Access

Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation

Kamal Alzahrani, Oren Pasvolsky, Zhongya Wang, Denái R Milton, Mark R Tanner iD, Qaiser Bashir iD, Samer Srour iD, Neeraj Saini, Paul Lin, Jeremy Ramdial iD, Yago Nieto iD, Hans C Lee iD und 9 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19384 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Kamal Alzahrani und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation, Neoplasm Staging, Transplantation, Autologous. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, Paula and Rodger Riney Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The second revision of the International Staging System (R2‐ISS) is a simple tool to risk‐stratify newly diagnosed multiple myeloma (NDMM) patients. Here, we completed a retrospective analysis to evaluate the utility of R2‐ISS in NDMM patients who underwent up‐front autologous haematopoietic stem cell transplantation (auto‐HCT). A total of 1291 patients were included, with a median age of 62 years (range 29–83). The distribution of R2‐ISS stages was: 123 (10%) stage I, 471 (36%) stage II, 566 (44%) stage III and 131 (10%) stage IV. With a median follow‐up of 42.2 months (range 0.3–181.0), the median PFS was 73.0, 65.2, 44.0 and 24.8 months, ( p < 0.001) and the median OS was 130.8, 128.5, 94.2 and 61.4 months ( p < 0.001) for patients with R2‐ISS stages I, II, III and IV respectively. On multivariable analysis (MVA) for PFS, using R2‐ISS stage I as reference, R2‐ISS stages III (hazard ratio [95% confidence interval], 1.55 [1.05–2.29]; p = 0.028) and IV (2.04 [1.24–3.36]; p = 0.005) were associated with significantly inferior PFS. In the MVA of OS, using R2‐ISS stage I as reference, only R2‐ISS stage IV was associated with significantly inferior OS (2.43 [1.18–5.01]; p = 0.017). Overall, we found that R2‐ISS is a reliable prognostic tool for NDMM patients undergoing up‐front auto‐HCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHematopoietic Stem Cell TransplantationNeoplasm StagingTransplantation, AutologousHumansMiddle AgedAgedFemaleMaleAdultRetrospective StudiesAged, 80 and overRisk AssessmentTreatment Outcome

Stichwörter der Autor:innen

International Staging SystemR2‐ISShaematopoietic stem cell transplantationmultiple myeloma

Autor:innen und Institutionen

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Adult Hematology and Bone Marrow Transplant, King Fahad Medical City (KFMC), Riyadh, Saudi Arabia.
  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Mark R Tanner, Qaiser Bashir, Samer Srour, Jeremy Ramdial, Yago Nieto, Hans C Lee, Robert Z Orlowski, Muzaffar H Qazilbash

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Paula and Rodger Riney Foundation
  • Leukemia and Lymphoma Society
  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

Zitieren

APA

Alzahrani, K., Pasvolsky, O., Wang, Z., Milton, D. R., Tanner, M. R., Bashir, Q., Srour, S., Saini, N., Lin, P., Ramdial, J., Nieto, Y., Lee, H. C., Patel, K. K., Manasanch, E. E., Kebriaei, P., Thomas, S. K., Weber, D. M., Orlowski, R. Z., Shpall, E. J., …, & Qazilbash, M. H. (2024). Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. British Journal of Haematology. https://doi.org/10.1111/bjh.19384

Vancouver

Alzahrani K, Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, et al. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. British Journal of Haematology. 2024. doi:10.1111/bjh.19384

BibTeX
@article{Alzahrani2024,
  author = {Alzahrani, Kamal and Pasvolsky, Oren and Wang, Zhongya and Milton, Denái R and Tanner, Mark R and Bashir, Qaiser and Srour, Samer and Saini, Neeraj and Lin, Paul and Ramdial, Jeremy and Nieto, Yago and Lee, Hans C and Patel, Krina K and Manasanch, Elisabet E and Kebriaei, Partow and Thomas, Sheeba K and Weber, Donna M and Orlowski, Robert Z and Shpall, Elizabeth J and Champlin, Richard and Qazilbash, Muzaffar H},
  title = {Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19384}
}
Kostenlos starten →